Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun 15;60(12):1860-3.
doi: 10.1093/cid/civ155. Epub 2015 Feb 26.

Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study

Anne F Luetkemeyer  1 , Susan L Rosenkranz  2 , Darlene Lu  2 , Beatriz Grinsztejn  3 , Jorge Sanchez  4 , Michael Ssemmanda  5 , Ian Sanne  6 , Helen McIlleron  7 , Diane V Havlir  1 , David W Haas  8 ; Adult AIDS Clinical Trials Group A5221 and A5243 Study Teams
Affiliations

Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study

Anne F Luetkemeyer et al. Clin Infect Dis. .

Abstract

In STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow metabolizer genotypes in both genes had markedly elevated concentrations.

Keywords: HIV/AIDS; efavirenz; pharmacogenetic; rifampin; tuberculosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Efavirenz Cmin µg/mL by A, CYP2B6 genotype, B, NAT2 genotype, and C, Both CYP2B and NAT2 genotypes: Grey lines connect within-participant efavirenz Cmin on-antituberculosis therapy and off-antituberculosis therapy. Solid black lines indicate median on-antituberculosis therapy and off-antituberculosis therapy Cmin. *Indicate the 10 participants with 2 intermediate (INT) NAT2 alleles (categorized in this analysis as slow metabolizers). Abbreviations: EXT, extensive; TB, tuberculosis.
See this image and copyright information in PMC

References

    1. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva, 2013. - PubMed
    1. DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2014.
    1. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365:1482–91. - PMC - PubMed
    1. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365:1492–501. - PMC - PubMed
    1. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365:1471–81. - PMC - PubMed

Publication types

MeSH terms